Latest Safety News

WA1 Resources reports exceptional assay results from the Luni Niobium Project alongside significant pre-development progress and government recognition as a Major Project.

Meeka Metals delivered a robust December quarter with a 28% jump in gold production and nearly doubled operating cash flow, while exploration at new targets hints at further resource expansion.

Elsight Limited capped 2025 with record quarterly revenue and a substantial US$21.2 million contract, signalling robust growth and expanding global defence engagements heading into 2026.

Talius Group reported a positive operating cash flow for the December quarter, alongside a 3% rise in subscriptions and a $4 million capital placement. The company also announced a CEO succession and expanded its international footprint with new pilot programs.

Karoon Energy delivered 2025 production near the upper guidance range, marked by a leadership change and significant operational improvements. The company outlines cautious yet optimistic 2026 growth and cost guidance amid ongoing maintenance and exploration activities.

Actinogen Medical has locked in a $4.3 million tranche of non-dilutive funding to support its pivotal Alzheimer’s disease trial, reinforcing its financial position as it nears critical interim and final results.

PC Gold Ltd has secured approvals to re-open the historical Spring Hill underground adit, enabling cost-effective underground drilling to assess high-grade gold mineralisation and potentially expand its resource base.

Ioneer Ltd has reported a significant uplift in the economics of its Rhyolite Ridge lithium-boron project, alongside ongoing strategic partnership talks and strong market demand for lithium and boric acid.

Cycliq Group Ltd reported a 21% decline in customer receipts for Q2 FY2026, offset by a solid net operating cash inflow and a strong Black Friday campaign that generated $1.3 million in gross revenue.

Life360 has reported its strongest quarter ever, with record user and subscriber growth in Q4 2025, surpassing full-year revenue and EBITDA guidance. The company forecasts continued momentum with 20% user growth expected in 2026.

Anteris Technologies has completed a $90 million strategic investment from Medtronic as part of a $320 million capital raise, advancing its DurAVR transcatheter heart valve towards global commercialisation and pivotal clinical trials.

Anteris Technologies Global Corp. has entered a material definitive agreement to raise approximately $320 million through a public offering and a strategic private placement with Medtronic’s subsidiary. The capital will support clinical trials and manufacturing expansion for its innovative heart valve technology.